Industry Alliance Council

Our Industry Alliance council (IAC) improves access to therapies for sickle cell patients, aligns industry values, and supports education, advocacy, and research.

Industry Alliance Council

Our Industry Alliance council (IAC) improves access to therapies for sickle cell patients, aligns industry values, and supports education, advocacy, and research.

Industry Alliance Council

Our Industry Alliance council (IAC) improves access to therapies for sickle cell patients, aligns industry values, and supports education, advocacy, and research.

Enhancing Access & Advocacy

Over the years, the Sickle Cell Awareness Group of Ontario (SCAGO) has worked collaboratively with various industry partners and one of the outcomes of this collaboration is that more individuals living with SCD in the province of Ontario have improved access to life-saving and disease-modifying therapies.

Enhancing Access & Advocacy

Compared to a decade ago, we are witnessing more pharmaceuticals having an interest in sickle cell disease which is excellent for the sickle cell disease community not only in Canada but globally. The more innovative therapies for sickle cell disease in the pipelines, the more access patients will have to an increasing number of disease-modifying, life-enhancing and curative therapies.

Purpose of the Industry Alliance Council

To improve Access of SCD patients to innovative and

disease-modifying therapies, clinical trials, and research in Canada.

To better Align the values of the industry, researchers and the SCD patients.

To support SCD Education, Advocacy, and Research in Canada.

As a leading sickle cell disease patient advocacy and support organization serving 60% of the Canadian sickle cell disease population, the Sickle Cell Awareness Group of Ontario finds it imperative to work even more cohesively with the industry partners, bringing them together in a formal advisory council with patients to better engage as a part of the sickle cell disease puzzle.